Perry Andrew
- SEC CIK
- 0001877793
No open-market purchases or sales filed in the past year.
Current role at each company
- GTHX G1 Therapeutics, Inc.Chief Commercial Officeras of Sep 18, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Perry Andrew as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 8, 2024 (view filing) | Jul 5 | 3 days | Perry AndrewChief Commercial Officer | SSale | −1.34K | $2.51 | −$3.36K | −1.2%112.6K after | |
| May 15, 2024 (view filing) | May 13 | 2 days | Perry AndrewChief Commercial Officer | SSale | −8.15K | $4.79 | −$39.0K | −9.4%79.0K after | |
| Jan 8, 2024 (view filing) | Jan 3 | 5 daysLate | Perry AndrewChief Commercial Officer | SSale | −2.41K | $3.12 | −$7.53K | −2.7%87.1K after | 2 lots |
| Jul 7, 2023 (view filing) | Jul 5 | 2 days | Perry AndrewChief Commercial Officer | SSale | −355 | $2.45 | −$869.75 | −0.6%55.9K after | 10b5-1 |
| Jan 5, 2023 (view filing) | Jan 4 | 1 day | Perry AndrewChief Commercial Officer | SSale | −820 | $5.58 | −$4.58K | −3.7%21.3K after |